Primary Immunodeficiency Disorders Market To Reach $11.14 Billion By 2030

Primary Immunodeficiency Disorders Market Growth & Trends

The global primary immunodeficiency disorders market size is expected to reach USD 11.14 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 6.4% from 2024 to 2030. The industry is experiencing significant growth, driven by multiple key factors. Rising incidences of genetic disorders, increased awareness among healthcare professionals, and advancements in diagnostic and therapeutic technologies are pivotal in expanding the industry.

A study published in The New England Journal of Medicine in December 2022 highlights the success of gene therapy for Artemis-deficient severe combined immunodeficiency (ART-SCID). By adding a healthy copy of the DCLRE1C gene to patients' stem cells, this therapy effectively restored T and B cell function. The study, involving 10 infants, showed significant immune recovery and reduced complications compared to traditional treatments. Researchers are optimistic about the therapy’s potential, though further long-term studies and broader trials are needed for FDA approval and to explore its applicability in diverse populations. The successful gene therapy for Artemis-deficient SCID boosts industry growth by demonstrating effective treatment for previously difficult-to-treat conditions. This advancement drives demand for gene therapy solutions and innovations in treatments. The positive outcomes from this study potentially leading to increased investment, broader adoption, and the development of new therapies, thereby expanding the industry for advanced treatments.

Moreover, several drug’s success highlights the potential for similar innovations, fostering industry expansion and encouraging further development of specialized therapies in the sector. For instance, in March 2023, Pharming Group leniolisib (Joenja) approved by the FDA as the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) in patients aged 12 and older. The approval follows a 12-week study demonstrating that leniolisib reduced lymph node size and improved naïve B cell counts by 37% compared to placebo. The industry is expanding due to advancements in gene therapy and the approval of new treatments such as leniolisib. These innovations demonstrate effective solutions for previously difficult-to-treat conditions, driving increased investment and interest in the sector. The success ofthese therapies boosts market confidence and encourages further development of specialized treatments. As research progresses and new therapies emerge, the market for advanced immunodeficiency treatments is expected to continue its robust growth, ultimately benefiting patients and healthcare providers alike.

 Request a free sample copy or view report summary: Primary Immunodeficiency Disorders Market Report

Primary Immunodeficiency Disorders Market Report Highlights

• Based on region, North America accounted for largest market share of 45.39% in 2023. The market is driven by robust healthcare infrastructure, high prevalence, and proactive government initiatives in the region.

• Based on disease, antibody deficiency segment accounted for the largest share of 52.62% in disease segment in 2023. The growth can be attributed to its high prevalence, significant healthcare impact, and the development of targeted treatments. Increased awareness and advanced diagnostics also contribute to its substantial presence in the industry.

• Based on product, the immunoglobulin replacement therapy segment holds the largest share in the market accounted for 63.18% in 2023 owing to its essential role in managing antibody deficiencies. High demand for effective treatment, advancements in therapy, and the critical need for ongoing care contribute to its substantial market share.

Primary Immunodeficiency Disorders Market Segmentation

Grand View Research has segmented the global primary immunodeficiency disorders market on the basis of disease, treatment, and region:

Primary Immunodeficiency Disorders Disease Outlook (Revenue, USD Billion; 2018 - 2030)

• Antibody Deficiency

• Cellular Immunodeficiency

• Innate Immune Disorders

• Others

Primary Immunodeficiency Disorders Treatment Outlook (Revenue, USD Billion; 2018 - 2030)

• Immunoglobulin Replacement Therapy

• Antibiotic Therapy

• Stem Cell/Bone Marrow Transplantation

• Gene Therapy

• Others

Primary Immunodeficiency Disorders Regional Outlook (Revenue, USD Billion; 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Norway

  • Denmark

  • Sweden

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Companies in the Primary Immunodeficiency Disorders Market

• Baxter International, Inc.

• CSL Behring LLC

• Takeda Pharmaceutical Company Limited

• Octapharma AG

• Biotest AG

• Grifols S.A.

• Kedrion Biopharma Inc.

• Bio Products Laboratory Ltd.

• LFB S.A.

• ADMA Biologics

• Astellas Pharma Inc.

• Abbott Laboratories